Flow Neuroscience develops a non-invasive brain stimulation technology called tDCS for the treatment of depression.

Flow Neuroscience

Parasym is a neurotechnology company focused on developing innovative neuromodulation treatment that significantly improves quality of life. Self-described as pioneering a new class of treatment that uses bioelectrical signals targeted to neural circuits of organs.

Parasym

BrainQ develops investigational therapy aimed at reversing disability after a stroke using AI-powered electromagnetic stimulation, self-described as a means to help users achieve freedom from disability from home.

BrainQ

Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

Metric
Company Name	Flow Neuroscience	Parasym	BrainQ	BrainsWay Ltd.
Symbol				BWAY
MSH ID	COM:FLOWNEUROSCIENCE	CO:PARASYM	COM:BRAINQTECH	COM:BRAINSWAY
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services	Healthcare
Industry	Mental Health Services	Medical Devices	Medical Devices	Medical - Devices
Country	GB	US	IL	IL
Stage
Employee Count				134
Website	flowneuroscience.com	parasym.co	brainqtech.com	brainsway.com
LinkedIn
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	77.08K
Web Traffic Growth	-0.37
Valuation
Raised Capital

Metric
Revenue				31.79M
Revenue (LTM)
Revenue (NTM)
Gross Profit				23.48M
EBITDA				-2.50M
Operating Income				4.96M
Net Income				-4.20M
EPS				-0.13
Diluted EPS				-0.13
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				0.75
Operating Profit Margin				0.29
EBITDA Margin				-0.08
Net Profit Margin				0.02
Return on Equity				0.01
Return on Assets				0.01
Return on Capital Employed				0.20

COM:FLOWNEUROSCIENCE

Flow Neuroscience

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				-11.70
P/B Ratio				2.32
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				4.56
EV Multiple				78.67

Metric
Days Sales Outstanding				43.33
Days Payables Outstanding				23.23
Days Inventory Outstanding				165.09
Operating Cycle				208.43
Cash Conversion Cycle				185.20
Asset Turnover				0.56

Metric
Operating Cash Flow				1.28M
Free Cash Flow				-1.10M
Cash Flow to Debt				2.73
Operating Cash Flow/Sales				0.23
Free Cash Flow Yield				-0.05

Metric
Cash & Equivalents				10.52M
Accounts Receivable				1.09M
Inventory				3.72M
Goodwill
Debt to Capitalization				0.11
Debt to Assets				0.08
Current Ratio				6.36
Quick Ratio				5.76

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue				0.02
R&D to Revenue				0.26
SG&A to Revenue				0.20